TMCnet - World's Largest Communications and Technology Community



RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
[July 02, 2014]

RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses

MIRAMAR BEACH, Fla. --(Business Wire)--

Work continues on a new injectable, sustained-release technology that Rainbow Coral Corp. (OTCBB: RBCC) hopes can help prevent a deadly epidemic of prescription narcotic overdoses.

In a statement to the press reported by Benzinga earlier this month, National Institute on Drug Abuse (NIDA) Director Nora Volkow said that opioid-receptor blocker Naltrexone can improve lives and reduce risks of overdose. Volkow called such medication-assisted therapies "markedly underutilized."

According to NIDA figures, drug overdose deaths in the U.S. are over 30,000 annually. In the past 20 years, overdoses of narcotic pain relievers have tripled, with an estimated 2.1 million people in the U.S. abusing opioid pain relievers.

RBCC is working on a new technology to help address the growing problem. Through its biotech subsidiary, Rainbow Biosciences, the company formed a joint venture with TheraKine, Ltd., to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone. Phase I of the joint venture's research established excellent compatibility between the drug and TheraKine's hydrophobic injection matrix, as well as a highly promising release profile. Phase II focused on micronization of the technology as well as extension of its sustained release time.

This summer,RBCC will focus on demonstrating the new technology's readiness for market as the number of prescriptions rise due to the Affordable Care Act.

RBCC's biotech division, Rainbow BioSciences, is working with partners such as TheraKine to capitalize on the incredible growth of the global drug delivery market by delivering new medical and research technology innovations in order to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Valeant Pharmaceuticals International (NYSE: VRX).

For more information on RBCC's other biotech initiatives, please visit

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy